1.
|
Phase: Phase IV Type: Treatment Status: Active Age: 15 to 65 Sponsor: Other Protocol IDs: GMALL01, NCT00198991
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MCC-14178, NCT00361140
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 21 and under Sponsor: Other Protocol IDs: SCT 0208, NCT00679536
|
|
5.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 4 to 70 Sponsor: Other Protocol IDs: RPCI-RP-9815, NCI-V99-1527, NCT00003816, RP 98-15
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: Over 60 Sponsor: Other Protocol IDs: 012000, NCT00382759
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 152CL201, NCT00391066
|
|
8.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: Any age Sponsor: Other Protocol IDs: UHW-AML16, EU-20677, ISRCTN11036523, EUDRACT-2005-002846-14, MREC-CU106, NCT00454480
|
|
9.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 19 to 70 Sponsor: Other Protocol IDs: F080429003, UAB-0775, NCT00714259
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: Under 75 Sponsor: NCI Protocol IDs: FHCRC-1813.00, 5666, NCT00075478
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: AML_CR2_allo_HSCT, NCT00125606
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 9005-2003, NCT00150878
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 230704-HMO-CTIL, NCT00226512
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 35 to 55 Sponsor: Other Protocol IDs: P040420, AOM04088, NCT00224614
|
|
15.
|
Phase: Phase III Type: Treatment Status: Active Age: 60 and over Sponsor: Other Protocol IDs: MCL2004-1, NCT00209209
|
|
16.
|
Phase: Phase III Type: Treatment Status: Active Age: 17 and under Sponsor: Other Protocol IDs: TRIAL, TRIAL Relapsed AML 2001/01, NCT00186966
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: Geriatric Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL9, EU-20561, AMGEN-GCLLSG-CLL9, EUDRACT-2005-003014-15, NCT00281892
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: GCLLSG-CLL7, EU-20559, ROCHE-GCLLSG-CLL7, EUDRACT-2005-003-018-14, NCT00275054
|
|
19.
|
Phase: Phase III Type: Treatment Status: Active Age: 65 and under Sponsor: NCI, NHLBI Protocol IDs: FHCRC-1992.00, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
|
|
20.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CALGB-10501, CALGB-10501, NCT00513747
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 1 to 21 Sponsor: NCI, NHLBI Protocol IDs: 467, BMT CTN 0501, 5 U01 HL69294-05, NCT00412360
|
|
22.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 65 and under Sponsor: Other Protocol IDs: 2005-0366, NCT00469144
|
|
23.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TSH-WM1, ISRCTN56052618, TSH-WM1, NCT00608374
|
|
24.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 21 and under Sponsor: Other Protocol IDs: AML SCT-BFM 2007, EudraCT: 2007-004517-34, NCT00606723
|
|
25.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CRUK-UCL-MCLIII, CRUK-UCL-MCLIII, EUDRACT-2006-001965-41, MREC-02/6/31, EU-20824, NCT00641095
|